Can barbiturates (barbituric acid derivatives) cause lactic acidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Barbiturates Cause Lactic Acidosis?

Barbiturates themselves do not directly cause lactic acidosis through their pharmacologic mechanism, but propylene glycol—a diluent used in intravenous barbiturate formulations like pentobarbital—can cause severe lactic acidosis when administered in high doses or prolonged infusions.

Direct Barbiturate Effects

  • Barbiturates are derivatives of barbituric acid that primarily cause respiratory and cardiovascular depression through suppression of medullary centers, but they do not directly induce lactic acidosis as a pharmacologic effect 1.

  • The main toxic effects of barbiturates include respiratory depression leading to potential tissue hypoxia, cardiovascular depression with hypotension, and CNS depression 1.

  • While severe barbiturate overdose could theoretically cause secondary type A lactic acidosis through tissue hypoxia from profound respiratory or cardiovascular collapse, this is not a characteristic or commonly reported feature of barbiturate toxicity 1.

Propylene Glycol-Induced Lactic Acidosis: The Real Culprit

The critical issue is that intravenous pentobarbital contains 40% v/v propylene glycol as a vehicle, and this diluent is the actual cause of lactic acidosis in patients receiving continuous pentobarbital infusions 2.

Mechanism of Propylene Glycol Toxicity

  • Propylene glycol is eliminated through oxidation by alcohol dehydrogenase to form lactic acid, which under normal conditions is converted to pyruvate and metabolized through the Krebs cycle 3.

  • When propylene glycol accumulates from high-dose or prolonged infusions (particularly in patients with renal dysfunction), it overwhelms metabolic capacity and causes severe lactic acidosis 2, 3.

Clinical Presentation

  • Propylene glycol toxicity presents with anion gap metabolic acidosis, elevated serum lactate, hyperosmolality, and increased osmolal gap 2.

  • This typically occurs 12-24 hours after starting continuous pentobarbital infusions, particularly at doses of 10 mg/kg/hour or higher 2.

Management of Propylene Glycol-Induced Lactic Acidosis

  • Immediately discontinue the pentobarbital infusion when propylene glycol toxicity is suspected 2.

  • Fomepizole should be initiated to inhibit alcohol dehydrogenase and prevent further conversion of propylene glycol to lactic acid 3.

  • Continuous venovenous hemofiltration (CVVH) or continuous renal replacement therapy effectively removes both propylene glycol and lactate 3.

  • Resolution of acidosis typically occurs within 24-72 hours after discontinuation of the offending agent and initiation of appropriate treatment 2, 3.

Clinical Pitfalls and Monitoring

  • Clinicians must recognize that the pentobarbital formulation itself (50 mg/mL in a vehicle of propylene glycol, alcohol, and water) poses the risk, not the barbiturate molecule 4, 2.

  • Patients receiving continuous pentobarbital infusions require monitoring for signs of propylene glycol toxicity, including serial lactate levels, osmolal gap calculations, and arterial blood gases 2.

  • Risk factors include renal dysfunction, prolonged infusions (>24-48 hours), and high infusion rates 2, 3.

  • Iatrogenic overdoses of lorazepam (another propylene glycol-containing medication) have resulted in propylene glycol levels as high as 659 mg/dL with severe lactic acidosis (pH 6.9, lactate 18.6 mmol/L) 3.

Other Barbiturate Formulations

  • Not all barbiturate formulations contain propylene glycol; phenobarbital for oral use does not carry this risk 1, 4.

  • The lactic acidosis risk is specific to intravenous formulations containing propylene glycol as a diluent 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Barbiturate Pharmacology and Clinical Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.